Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of feglymycin in China, also supports custom service. Welcome to wholesale bulk high quality feglymycin from our factory. Contact us for more details.
| Description | Lynronne-2 is an antimicrobial peptide identified from the human microbiome, sequence His-Leu-Arg-Arg-Ile-Asn-Lys-Leu-Leu-Thr-Arg-Ile-Gly-Leu-Tyr-Arg-His-Ala-Phe-Gly-NH₂ (one-letter: HLRRINKLLTRIGLYRHAFG-NH2), with the C-terminal carboxyl group amidated, totaling 20 amino acid residues, with a theoretical molecular weight of 2433.90 Da. Lynronne-2 belongs to the Lynronne antimicrobial peptide family (including Lynronne-1, -2, and -3), a family of natural antimicrobial peptides discovered from the microbiome. Similar to Lynronne-1 (LPRRNRWSKIWKKVVTVFS), the sequence of Lynronne-2 exhibits typical amphipathic alpha-helical peptide characteristics: the sequence contains 4 arginine residues (Arg) and 2 lysine residues (Lys), with a high net positive charge; it also contains multiple hydrophobic amino acids (4 leucines, 2 isoleucines, 2 phenylalanines, 1 alanine, 1 tyrosine), capable of forming an amphipathic alpha-helical structure in a membrane environment. C-terminal amidation eliminates the negative charge of the C-terminal carboxyl group, increasing the net positive charge of the peptide, facilitating binding to negatively charged microbial cell membranes. Lynronne-2 exhibits antimicrobial activity against Gram-positive bacteria, including multi-drug resistant (MDR) strains: the minimum inhibitory concentration (MIC) for methicillin-resistant Staphylococcus aureus (MRSA) strains is 32-256 μg/mL. In addition, Lynronne-2 is also effective against Pseudomonas aeruginosa infections. Studies have shown that Lynronne family antimicrobial peptides possess antimicrobial activity against all tested clinical strains of Acinetobacter baumannii (an important drug-resistant superbug) with MICs of 2-128 μg/mL, and also exhibit anti-biofilm activity. The antimicrobial mechanism of Lynronne-2 primarily involves selective disruption of bacterial cell membranes: as a cationic amphipathic alpha-helical peptide, Lynronne-2 interacts electrostatically with negatively charged lipopolysaccharides (LPS, Gram-negative bacteria) or teichoic acids (Gram-positive bacteria) on the bacterial cell membrane surface through its positively charged arginine and lysine residues, and then forms an amphipathic alpha-helical structure on the cell membrane surface, inserting into the cell membrane lipid bilayer through the hydrophobic face, leading to increased cell membrane permeability, depolarization, and content leakage, ultimately resulting in bacterial death. Lynronne-2 exhibits selectivity for bacterial cells with low toxicity to mammalian cells (low hemolytic activity). Lynronne-2 is widely used in novel antibiotic development (particularly against drug-resistant bacteria such as MRSA and A. baumannii), microbiome antimicrobial peptide mining, anti-biofilm research, antimicrobial peptide structure-activity relationship research, and drug-resistant bacterial infection treatment research. |
| Molecular formula | C₁₀₉H₁₇₆N₃₂O₂₂ |
| Molecular weight (Da) | 2433.90 |
| Structure type | Linear 20-mer peptide (C-terminally amidated, microbiome-derived cationic amphipathic alpha-helical antimicrobial peptide, containing 4 arginines and 2 lysines, anti-MRSA) |
| Solubility | Freely soluble in water, PBS, DMSO |
| Storage | -20°C, dry, protected from light |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| Feglymycin | Feglymycin polypeptide antibiotic | Antimicrobial peptide, Gram‑positive targeting, peptidoglycan synthesis inhibition, antibiotic potentiation, anti‑resistant bacteria | Acidic polypeptide antibiotic from Streptomyces; exerts bactericidal effect by specifically binding bacterial peptidoglycan precursor Lipid II and inhibiting cell wall peptidoglycan synthesis; highly potent against Gram‑positive bacteria including MDR strains, and synergistic with β‑lactam antibiotics | C₅₃H₆₈N₈O₁₉ | 1140.46 | ~1141.3 | Free peptide | 9 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-FEGLY | White powder | Store at -20°C, sealed, dry and protected from light. Aliquot for storage. | Stable for 1 month at 2–8°C in sealed dry condition; stable for shipping at ambient temperature. | Stable for 7 days at 4°C. Free acidic peptide soluble in alkaline buffers and methanol. High affinity for bacterial peptidoglycan precursors; avoid co-incubation with peptidoglycan components to prevent activity neutralization. | Stable for 2 years at -20°C, dry and protected from light. |
Functional Description
| Product Code | Frontend Short Summary (for search list display) | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-FEGLY | Feglymycin polypeptide antibiotic targeting peptidoglycan synthesis against resistant Gram-positive bacteria | Feglymycin is an acidic polypeptide antibiotic from Streptomyces that targets Lipid II, the key precursor of bacterial peptidoglycan synthesis. It blocks transglycosylation and transpeptidation by binding Lipid II, inhibiting cell wall synthesis and causing bacterial lysis. It is potent against MRSA and other Gram-positive MDR strains and synergizes with conventional antibiotics. | Gram-positive bacterial infections, resistant bacteria therapy, antibiotic potentiation, peptidoglycan synthesis mechanism, natural product antibiotics | Bacterial peptidoglycan precursor Lipid II; cell wall synthesis inhibition; bacterial lysis pathway |
Hot Tags: feglymycin, China feglymycin manufacturers, suppliers, factory, 143459-88-5, 849352-44-9, CAS 143459 88 5, CAS 849352 44 9, Cilofungin, CP7-FP13-2
